Moderna Stock Rises After mRNA Flu Shot Approval -- WSJ
Dow Jones2026/08/06 13:56By Xavier Martinez
Shares in Moderna ticked higher after the biotech secured Food and Drug Administration approval for its mRNA flu vaccine for use in adults aged 50 and older.
The FDA's decision capped an arduous seven-month process that included a rare refusal by the regulator to consider the shot. The agency agreed to review it after Moderna said it would conduct a follow-up trial confirming the vaccine's effectiveness among the elderly.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
August 06, 2026 09:56 ET (13:56 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
G Square buys 82% stake in Valtecne, plans delisting tender offer
D2L Swings to Q2 Loss, Revenue Misses Estimates; Cuts Full-Year Revenue Outlook
Chemours, DuPont, Corteva settle North Carolina PFAS lawsuits for USD 455 million
Welltower Care Home Acquisitions Avoid In-Depth UK CMA Investigation
Crypto prices
More
